Announcements

Announcements

EDCTP    [to 3 March 2018]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
28 February 2018
Investments in health research for better health: current benefits and future potential of engagement with EDCTP in the East Africa Community
The East Africa Community (EAC) convened its 19th Summit of EAC Heads of State and Joint Retreat on Infrastructure and Health Financing and Development on 21-23 February 2018 in Kampala Uganda. The Retreat on 22 February was preceded by the first Round Table on ‘investing in health infrastructure, systems, services and research for the accelerated attainment of universal health coverage and sustainable development goals’ on 21 February. The Round table programme contributed to the discussions at the Joint EAC Heads of State Retreat the next day. EAC presented its Priority Framework 2018-2028 for investment in the health sector.

European Medicines Agency  [to 3 March 2018]
http://www.ema.europa.eu/ema/
02/03/2018
EMA urgently reviewing multiple sclerosis medicine Zinbryta following cases of inflammatory brain disorders
Medicine to be voluntarily withdrawn from the market by the company …

26/02/2018
Towards more ethical use of animals in medicine testing
First report on EMA’s actions to replace, reduce, refine use of animals in medical research …
 
 
 
FDA [to 3 March 2018]
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm
February 26, 2018 –
Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA’s ongoing efforts to help improve effectiveness of influenza vaccines
 
 
Fondation Merieux  [to 3 March 2018]
http://www.fondation-merieux.org/
March 2, 2018
The National Laboratories Directorate and the Continuing Training Center for laboratory technicians are being inaugurated on Friday 2, March, in Guinea. They are part of RESAOLAB (West African Network of Biomedical Analysis Laboratories) and are housed in the Institute for the Professional Development of Healthcare Providers in Conakry.
 
February 28, 2018
The WASH working group of the Global Task Force on Cholera Control (GTFCC) meets on February 27 and 28 to discuss the challenges of improving water, sanitation and hygiene in countries where cholera is endemic. The meeting will be an opportunity to present an update on the GTFCC and the Ending Cholera Roadmap, which aims to reduce deaths from cholera by 90% by 2030.
 
 
Gavi [to 3 March 2018]
http://www.gavi.org/library/news/press-releases/
02 March 2018
Call for new ID technology to help immunise every child
Apply before 10 April to grow your innovation with INFUSE.
Geneva, 2 March 2018 – Gavi, the Vaccine Alliance is calling for talented problem solvers, entrepreneurs and established corporations to help immunise the world’s most vulnerable children. As part of its 2018 call, INFUSE (or, Innovation for Uptake, Scale and Equity in immunisation) – Gavi’s innovation acceleration platform – is looking for new proven digital technology for registration and verification of identity to accelerate and improve immunisation coverage and delivery.

While more children than ever before are protected with life-saving vaccines, an estimated 1.5 million children still die annually from vaccine preventable diseases. To ensure that all children have access to immunisation we will require better insight into which children are missing out. A common challenge in many developing countries is that an increasing number of people live in communities not well served or under the radar, invisible to often outdated, paper-based methods used to certify births, deaths and marriages.

“One in three children under age five does not officially exist because their birth wasn’t registered. This can have a lasting impact on children’s lives, leaving them vulnerable to neglect and abuse. But most importantly, we cannot vaccinate the children who we do not know exist”, said Gavi CEO Dr Seth Berkley.

“We need affordable, secure digital identification systems that can store a child’s medical history, and that can be accessed even in places without reliable electricity”, he added.

Do you have a proven solution which addresses this issue and is ready to scale-up at a national, regional or global level? Then we need you to be part of INFUSE 2018 and help us protect the world’s most vulnerable children.
 
 
IVI   [to 3 March 2018]
http://www.ivi.int/
[Undated]
Sida provides increased unrestricted funding of US$620,000 in 2018
IVI is pleased to announce that Sida**, the Swedish International Development Agency, is providing a further unrestricted contribution of SEK5 million (US$620,000) that the Institute will use to support three special high-priority projects in 2018.
These three new projects will include IVI laboratory assays to support a post-licensure study of the safety and effectiveness of Dengvaxia®* in dengue primed and non-primed children in Cebu, Philippines, ‘Modeling of the impact and cost-effectiveness of WHO’s “Ending Cholera – A Global Roadmap to 2030” strategy’ and ‘Conduct of a global economic burden assessment on antimicrobial resistance to typhoid fever treatments.’
*Dengvaxia®, manufactured by Sanofi Pasteur, is the only licensed dengue vaccine and to-date has been introduced in subnational public health programs in two countries; the Philippines and Brazil. Despite its overall positive public health impact in highly endemic settings, concerns have arisen about disease enhancement in dengue naïve vaccine recipients. The IVI project in Cebu will test blood samples collected prior to Dengvaxia® implementation to assess the effect of dengue primed status on vaccine safety. The results could make a significant contribution to our understanding of dengue, dengue hemorrhagic fever and potential interactions with dengue vaccines.
The second study on modeling and economic evaluation of cholera is expected to provide evidence on the value of investments and inform strategic decisions on cholera elimination and development of new vaccines. With antimicrobial resistance (AMR) being one of the biggest threats to global health, the third project will seek to estimate the economic implications of AMR on typhoid fever. These two projects will be led by IVI’s Policy and Economic Research (PER) Department.
**Sida is a long-term funder of IVI and is providing the Institute with support of SEK 35.5 million over the 5 years to 2019 in addition to this supplemental funding.
 
 
JEE Alliance  [to 3 March 2018]
https://www.jeealliance.org/
24.1.2018
Alliance successes in 2017 and an update on 2018
The year 2017 was the first full year of the work of the JEE Alliance. During the year, 15 new members joined the Alliance, contributing the wealth of expertise and experience. There are now 68…
 
 
MSF/Médecins Sans Frontières  [to 3 March 2018]
http://www.doctorswithoutborders.org/news-stories/press/press-releases
Press release
Nigeria: MSF Suspends Medical Activities in Rann Following Attack
GENEVA/NEW YORK, MARCH 2, 2018—Following a violent attack yesterday near Rann, in Nigeria’s Borno state, Doctors Without Borders/Médecins Sans Frontières (MSF) suspended its medical activities in the town and evacuated 22 Nigerian and international staff.
It is still unclear how many people were killed and injured in the attack, but before leaving, MSF medical staff treated nine wounded patients.

 
NIH  [to 3 March 2018]
http://www.nih.gov/news-events/news-releases
February 28, 2018
NIAID unveils strategic plan for developing a universal influenza vaccine
February 28, 2018 — Developing a vaccine that can provide durable protection for all age groups against multiple influenza strains is a priority.
[Please see Milestones above for full text]

NIH researchers find a potential treatment for disorders involving excess red blood cells
February 26, 2018 — Study in mice suggests that experimental drug may be effective against mountain sickness and other polycythemias.
 

UNAIDS [to 3 March 2018]
http://www.unaids.org/en
27 February 2018
Five-point plan to prevent and address all forms of harassment for greater accountability and transparency within UNAIDS

27 February 2018
A call for an HIV catch-up plan for the First Nations in Canada

26 February 2018
Partnership connects African law schools to the AIDS response

UNICEF  [to 3 March 2018]
https://www.unicef.org/media/
1 March 2018
Nearly 19 million newborns at risk of brain damage every year due to iodine deficiency
NEW YORK, 1 March 2018 – Nearly 19 million babies born globally every year – 14 per cent – are at risk of permanent yet preventable brain damage and reduced cognitive function due to a lack of iodine in the earliest years of life, according to a new joint report by UNICEF and GAIN released today. More than 1 in 4 of these children – 4.3 million – lives in South Asia.

Vaccine Confidence Project  [to 3 March 2018]
http://www.vaccineconfidence.org/
Confidence Commentary
To wipe out measles, governments must regain social trust
Heidi Larson | 28 Feb, 2018
[See Report, Research, Commentary below for full text]

Wellcome Trust  [to 3 March 2018]
https://wellcome.ac.uk/news
News / Published: 28 February 2018
Public Engagement Fund to relaunch with tighter focus on outcomes
Wellcome’s Public Engagement Fund is reopening on 5 March after being closed briefly. We’ve changed elements of how we’re going to run the scheme and what we’re looking for. In particular, we want applicants to be clearer about the change they are going to make in the world.
This reflects a strategic shift by Wellcome’s Public Engagement team towards involving the public in ways that will best support our mission of improving health.